Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
The analyst points out that DurAVR, positioned as an emerging next-gen TAVR player, is on track to capture 4%-5% of the U.S. TAVR market by 2030.Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. (NASDAQ:AVR) with a Positive rating and a forecast of $22.
巴克萊銀行分析師Matt Miksic對安泰瑞斯科技全球公司（納斯達克：AVR）進行了正面評級，並預測其價格爲22美元。
The analyst notes that Anteris Technologies' DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028
分析師指出，安泰瑞斯科技的DurAVR閥門系統預計將在2028年成爲第二個氣囊可擴展經導管閥置換（BEV TAVR）系統。
Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems from Medtronic plc. (NYSE:MDT) and Abbott Laboratories (NYSE:ABT).
臨牀醫生明顯偏愛氣囊可擴展（BEV）TAVR系統，而非來自美敦力公司（紐交所：MDT）和雅培（紐交所：ABT）的自擴展（SEV）系統。
The analyst points out that DurAVR, positioned as an emerging next-gen TAVR player, is on track to capture 4%-5% of the U.S. TAVR market by 2030.
分析師指出，DurAVR作爲新興的下一代TAVR參與者，有望在2030年前獲得美國TAVR市場的4%-5%。
Despite strong data from MDT in 2024, clinicians still favor balloon-expandable (BEV) TAVR systems, of which DurAVR is set to be the second.
儘管在2024年有來自MDt的強勁數據，臨牀醫生仍然偏愛氣囊可擴展（BEV）TAVR系統，而DurAVR將成爲第二個此類系統。
Also Read: Meta Drops Fact-Checking For Community Notes: Zuckerberg Sees 'Opportunity To Restore Free Expression'
另見：Meta取消社區筆記的事實覈查：扎克伯格看到『恢復自由表達的機會』
The analyst estimates that in the U.S., around 130,000 isolated aortic valve replacement (AVR) procedures are performed annually, out of about 550,000 patients with symptomatic severe aortic stenosis (ssAS). Additionally, 175,000 new ssAS patients are diagnosed each year, while 100,000 patients die annually due to lack of treatment.
分析師估計，在美國，每年約有130,000例孤立性主動脈瓣置換（AVR）手術，而大約有550,000例患者患有症狀嚴重的主動脈狹窄（ssAS）。此外，每年有175,000名新ssAS患者被診斷，同時每年有100,000名患者因缺乏治療而死。
Although TAVR market growth has slowed, the analyst sees the market as underpenetrated and views it as a promising target for the next-gen DurAVR platform.
雖然TAVR市場增長放緩，分析師認爲市場仍然被低估，並將其視爲下一代DurAVR平台的一個有希望的目標。
In addition to its BEV delivery system, DurAVR offers superior hemodynamics and laminar blood flow, combining the best features of leading TAVR platforms for more favorable hemodynamics and a low-profile valve height.
除了其BEV交付系統外，DurAVR還提供優越的血液動力學和層流血流，結合了領先TAVR平台的最佳特性，以實現更有利的血液動力學和低輪廓閥門高度。
Early clinical evidence suggests that DurAVR could outperform other leading TAVR platforms in areas such as hemodynamics, outcomes in valve-in-valve (VIV) procedures and potentially in long-term durability, thanks to the company's proprietary ADAPT tissue technology, Miksic writes.
早期臨牀證據表明，DurAVR在血液動力學、閥門內閥門（VIV）程序的結果以及長期耐久性等領域可能超過其他領先的TAVR平台，這要歸功於公司專有的ADAPt組織技術，Miksic寫道。
For FY25, the analyst estimates the company to report a loss of $(1.30) per share.
根據分析師的預測，該公司在2025財年每股預計虧損$(1.30)。
Price Action: AVR shares are trading higher by 2.67% to $5.760 at last check Tuesday.
價格走勢：週二最後檢查時，AVR股票上漲2.67%，至$5.760。
Read now:
現在閱讀：
- AMD Unveils 'Next Generation' AI Processors, Gaming Gear Ahead Of CES 2025
- AMD在2025年CES前發佈了「下一代」人工智能處理器和遊戲設備
Anteris logo courtesy of company
Anteris徽標由公司提供
譯文內容由第三人軟體翻譯。
